Welcome to our dedicated page for McKesson news (Ticker: MCK), a resource for investors and traders seeking the latest updates and insights on McKesson stock.
McKesson Corporation (MCK) delivers vital healthcare supply chain solutions through pharmaceutical distribution, medical-surgical product management, and technology services. This page provides investors and industry observers with direct access to McKesson's official news updates and market-moving developments.
Track earnings announcements, strategic partnerships, and regulatory filings alongside operational milestones shaping McKesson's role in healthcare logistics. Our curated feed consolidates press releases and verified news to help stakeholders monitor the company's performance in pharmaceutical wholesale and healthcare IT innovation.
Discover updates on McKesson's supply chain optimization initiatives, technology platform enhancements, and collaborations with hospitals, pharmacies, and manufacturers. Bookmark this page for efficient monitoring of developments impacting one of North America's leading healthcare distribution networks.
McKesson (NYSE:MCK) has announced a 15% increase in its quarterly dividend to $0.71 per share, up from $0.62 in the previous quarter. The dividend will be payable on October 1, 2024, to stockholders of record on September 2, 2024. This marks McKesson's eighth consecutive annual dividend increase, reflecting the company's confidence in its business fundamentals and financial strength. CEO Brian Tyler emphasized McKesson's commitment to a disciplined capital deployment strategy, focusing on growth and shareholder value creation. The dividend hike underscores the company's strong balance sheet and robust free cash flow generation capabilities.
McKesson (NYSE: MCK) is set to release its first quarter fiscal 2025 financial results on August 7, 2024, after market close. A live webcast of the earnings conference call will be held at 4:30 PM Eastern Time, available on McKesson’s Investor Relations website. The webcast will cover financial results, including earnings release, financial tables, and a slide presentation.
McKesson announced the election of Dr. Deborah Dunsire to its board of directors, effective June 3, 2024. Dr. Dunsire, with over 30 years of experience in the biopharmaceutical and oncology sectors, will also serve on the Compensation and Talent Committee and Finance Committee. She recently retired as CEO of H. Lundbeck A/S and has held leadership roles at XTuit Pharmaceuticals, FORUM Pharmaceuticals, and Millennium: The Takeda Oncology Company.
Meanwhile, current board members Linda Mantia and Susan Salka will not stand for re-election at the 2024 Annual Meeting of Shareholders. The board size will reduce to 11 members, 10 of whom will be independent. McKesson's board chair, Donald Knauss, expressed gratitude for their contributions.
McKesson (NYSE: MCK) has reported its fiscal 2024 fourth quarter financial results. The earnings conference call for investors will be held today, May 7th. The company's financial results, along with a slide presentation, can be accessed on McKesson's Investor Relations website.
FAQ
What is the current stock price of McKesson (MCK)?
What is the market cap of McKesson (MCK)?
